Naples Global Advisors’s Pasithea Therapeutics KTTA Stock Holding History

Naples Global Advisors’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-531	Closed	-$5.09K	–	413
2023 Q3	$5.09K	Buy	+531	New	+$5.81K	﹤0.01%	397

Other funds holding KTTA

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Naples Global Advisors's KTTA Position: Q4 2023 in Review

Naples Global Advisors sold out of Pasithea Therapeutics (KTTA) in Q4 2023, closing a stake of 531 shares — an estimated $5.09K sold.

Naples Global Advisors first reported a position in KTTA in Q3 2023 and held it in 1 quarter. The position peaked at $5.09K in Q3 2023. 8 funds tracked by Wall St. Rank hold KTTA as of Q4 2023.

Naples Global Advisors reported no remaining Pasithea Therapeutics position as of Q4 2023 after selling out during the quarter.
Naples Global Advisors sold 531 Pasithea Therapeutics shares in Q4 2023, an estimated $5.09K.
Naples Global Advisors first reported a position in Pasithea Therapeutics in Q3 2023 and held it in 1 quarter.
Naples Global Advisors's Pasithea Therapeutics position peaked at $5.09K in Q3 2023.
8 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2023.

Based on Naples Global Advisors's 13F filing for Q4 2023, filed 11 Jan 2024.